> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Wants CNS Stimulant Abuse Deterrence Comments
- URL: https://www.fdaweb.com/fda-wants-cns-stimulant-abuse-deterrence-comments/
- Published: 2019-09-19T12:00:00.000Z
- Updated: 2026-09-15T01:51:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145042

FDA has established a public docket soliciting comments from patients, patient advocates, healthcare professionals, academics, researchers, the pharmaceutical industry and other government entities on considerations relating to the development and evaluation of abuse-deterrent formulations (ADF) of central nervous system stimulants. Comments are also sought on whether such products could play a role in addressing public health concerns related to prescription stimulant misuse and abuse, according to a *Federal Register* [notice](https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-20372.pdf?ref=fdaweb.com).

An agency [statement](https://www.fda.gov/news-events/fda-brief/fda-brief-fda-seeks-input-development-and-evaluation-abuse-deterrent-formulations-central-nervous?ref=fdaweb.com) says that although FDA has approved multiple ADF opioid analgesic products with language in the drug labeling stating that the products are expected to deter abuse via specific routes of administration, it has not approved similar labeling for any prescription stimulants.

The notice gives an overview of available postmarket data on the use, misuse, and abuse of prescription stimulants and associated harms, with data on opioid analgesics provided for context. It also provides background information on the development and evaluation of ADF products and questions for which the agency is seeking input.